This part is right up your alley Kmall!

[biopearl123]

“ Depending on the stage of development of the product any available clinical data in a relevant population of patients can be provided. Applicants are strongly encouraged to include the views from patients or patient organisations around the benefits of a product in their evidence, if available.”

You probably have plenty of contacts from your “World Travels”.

I do think, especially with the publication of the aforementioned Annals of Hematology article looking at carefully matched RWD, that Geron will be or has already presented this peer reviewed data to the Brits. The EMA can watch the patients from Europe go to The Island Monarchy for their treatment.